Andrew Schorr interviews Professor Peter Hillmen at this year's Cologne iwCLL workshop on the changing role of MRD with the new treatments for CLL currently under trial.
Professor Peter Hillmen, from Leeds University in the United Kingdom, has been studying the role of minimal residual disease (MRD) in CLL for many years. When is it significant? And if it is significant, what do you do about it? Now, measuring MRD is becoming much more routine in CLL. Professor Hillmen explains its role today in helping patients get the longest possible remission.
patientpower.info/video/why...
This must be one of the last Patient Power videos to be released before those from the ASH2013 conference. If you've got a question you want answered by world experts attending ASH, please reply with your question to the below post ASAP.
healthunlocked.com/cllsuppo...
Thanks,
Neil
Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. 
